ALK Antibody / Anaplastic Lymphoma Kinase

Immunohistochemistry (FFPE): 1-2ug/ml

Optimal dilution of the recombinant Anaplastic Lymphoma Kinase antibody should be determined by the researcher.

Anaplastic lymphoma kinase (ALK) is a receptor tyrosine kinase of the insulin receptor superfamily. ALK is typically expressed at low levels in regions of the developing central and peripheral nervous system. ALK may be activated in cancer through multiple mechanisms. The most common mechanism is through formation of a fusion protein from chromosomal translocations, as in the case of anaplastic large cell lymphoma (ALCL) and inflammatory myofibroblastic tumors. ALK may also be amplified through mutation, as in neuroblastomas. Various solid tumors, such as non-small cell lung carcinoma (NSCLC) and brain cancers were also found to aberrantly express ALK. ALK staining is present within both the nucleus and cytoplasm, and are positive in about 60% of ALCL. ALK protein expression by tumor cells is an independent prognostic factor that predicts a favorable outcome.

Purified

0.2 mg/ml in 1X PBS with 0.1 mg/ml BSA (US sourced), 0.05% sodium azide

Recombinant human ALK protein fragment corresponding to the cytoplasmic domain of the protein was used as the immunogen for the recombinant Anaplastic Lymphoma Kinase antibody.

This recombinant Anaplastic Lymphoma Kinase antibody is available for research use only.

Cell membrane

Protein A/G affinity

Q9UM73